An £8.7 million, five-year research collaboration led by the University of Edinburgh and FUJIFILM Diosynth Biotechnologies UK (FDB) will develop more cost-effective ways to make modern antibody-based medicines.
With the support of Edinburgh Innovations, the collaboration has won Prosperity Partnership funding from the Engineering and Physical Sciences Research Council (EPSRC) and the Biotechnology and Biological Sciences Research Council (BBSRC), both of which are part of UK Research and Innovation.
The partnership will use state-of-the-art analytical tools and engineering biology approaches to enable the cost-effective manufacturing of biological drugs.
Biological drugs based on recombinant DNA technology, which brings together genetic material from different sources, have transformed the treatment of life-limiting diseases including cancer, haemophilia and rheumatoid arthritis.
Tapping in to the expertise of some our finest scientists and researchers, including at Teesside’s FUJIFILM Diosynth Biotechnologies and the University of Edinburgh, this state-of-the-art collaboration will seek to accelerate the development of biological drugs to help treat those with life-limiting diseases such as cancer.
This is part of our efforts to put the funding and structures in place to ensure we build back better through innovation, drive local economic growth and cement the UK’s status as a science superpower.
– Business Secretary Kwasi Kwarteng.
Better, more cost-effective drugs
The University of Edinburgh has led a three-university partnership with FDB since 2018, supported by EI. FDB will work with the Universities of Edinburgh, Manchester and York to study and modify the commonly used Chinese hamster ovary (CHO) cell platform with the aim of making the manufacture of biological drugs easier and cheaper.
This major funding award shows the leading position of Edinburgh and our partners Manchester and York as successful collaborators with businesses and other organisations.
Only by working together can academic researchers and commercial businesses both maximise the impact of their work, for mutual benefit and common goals.
– Dr George Baxter, CEO, Edinburgh Innovations.
As well as the major impact this could have in terms of new drugs to treat various conditions, it represents a major economic opportunity with an increasing portion of all medicines, currently estimated at 20%, being biopharmaceuticals and the global biologics market predicted to reach a value of $319 billion this year.
The award of this grant unlocks the power of new technologies we have developed and applies them to this key industry challenge.
The aim is to better understand and improve one of the key cell-based manufacturing platforms of biopharmaceuticals. Ultimately it will mean that treatments and vaccines used by many millions of people worldwide will be easier and cheaper to manufacture.
– Susan Rosser, Professor of Synthetic Biology, University of Edinburgh, and Royal Academy of Engineering Chair in Emerging Technologies.
Nine Prosperity Partnerships were announced on 2 April by the UK government, funded with an investment of £75 million from business, academia and UK Research and Innovation.
They will build on existing UK strengths in industry and academia to develop new technologies, processes, and skills that will deliver economic growth and create jobs in areas across the UK.
We are delighted with the partnership we have with the University of Edinburgh and it is aligned with our core purpose to advance tomorrow’s medicines. We are a supporter of great science in the United Kingdom.
This is an exciting project that will allow us to understand, model and ultimately design CHO cells to be more efficient.
– Andy Topping, Chief Scientific Officer, FDB.
The University of Edinburgh's biotechnology expertise